Ospemifene: a novel selective estrogen receptor modulator for treatment of dyspareunia.

Women's health (London, England)

PubMedID: 25335541

Eder SE. Ospemifene: a novel selective estrogen receptor modulator for treatment of dyspareunia. Womens Health (Lond Engl). 2014;10(5):499-503.
Ospemifene is a novel, oral selective estrogen receptor modulator that has been approved in the USA for treatment of dyspareunia. The decline in estrogen during menopause creates vulvovaginal changes that can cause symptoms that adversely impact women psychosexually. Many women are reluctant to discuss painful sex and providers must proactively inquire about sexuality issues. Ospemifene has been shown to reverse changes associated with vulvovaginal atrophy and relieve symptoms of dyspareunia. Safety studies of treatment up to 52 weeks have shown ospemifene to be safe with no impact on endometrial hyperplasia/carcinoma, venous thrombotic events or pelvic organ prolapse. Further studies are needed to evaluate its role in bone and breast health.